| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC3954 | Oxs000675 | Novel inducer of differentiation in all six AML cell lines |
|
| DCC3955 | Oxt-328 | Novel sulindac derivative; anti-inflammatory and anti-cancer agent |
|
| DCC3956 | Oxyfedrine Hydrochloride | Vasodilator and β-adrenoreceptor agonist |
|
| DCC3957 | Oxyl Surfen | Antagonist of cell-surface heparan sulfate and heparin-protein interactions, reducing tau hyperphosphorylation and mitigating or delaying neuronal defects in tauopathies, including Alzheimer's disease |
|
| DCC3958 | Oxymetholone | Synthetic hormone with anabolic and androgenic properties |
|
| DCC3959 | Oxymorphindole | δ-Opioid receptor agonist |
|
| DCC3960 | P18in005 Hydrochloride | Novel p18(INK4C) inhibitor |
|
| DCC3961 | P18smi-21 | Novel INK4C inhibitor, specifically blocking the bioactivity of p18 protein |
|
| DCC3962 | P18smi-22 | Novel INK4C inhibitor, specifically blocking the bioactivity of p18 protein |
|
| DCC3963 | P18smi-41 | Novel INK4C inhibitor, specifically blocking the bioactivity of p18 protein |
|
| DCC3964 | P217564 | Second-generation active site-targeted covalent irreversible inhibitor of USP7 |
|
| DCC3965 | P-2281 Featured | Novel potent inhibitor of mTOR activity, significantly suppressing macroscopic and histologic abnormalities associated with chemically-induced murine ulcerative colitis. |
|
| DCC3966 | P2y1-in-16 | Novel P2Y1 Antagonist |
|
| DCC3967 | P505-15 Acetate | Selective spleen tyrosine kinase (SYK) inhibitor, suppressing leukocyte immune function and inflammation, and leading to a reduction in arthritis score and attenuated histological damage |
|
| DCC3968 | p53 Modulator 10d | Novel modulator of p53 activity, arresting at G2/M phase inducing delay of cell cycle progression |
|
| DCC3969 | P53 Reactivator C85 | Novel reactivator of mutant p53, fuctioning as a zinc metallochaperone (ZMC) with diminished copper binding that functions as a chemotherapy and radiation sensitizer |
|
| DCC3970 | P5-peptide | Novel inhibitor of atherogenesis and diabetes, significantly and specifically inhibiting αD-CEP binding |
|
| DCC3971 | P7 Peptide | Novel bFGF antagonist peptide, inhibiting breast cancer cell growth |
|
| DCC3972 | P7c3a20 | Neuroprotective agent, protecting ventral horn spinal cord motor neurons from cell death |
|
| DCC3973 | P97-in-17 | Novel potent inhibitor of the AAA+ ATPase p97 |
|
| DCC3974 | P97-in-23 | Novel potent inhibitor of the AAA+ ATPase p97 |
|
| DCC3975 | Pa Autoinducer | Pseudomonas aeruginosa autoinducer |
|
| DCC3976 | Pa-082 | Novel partial agonist of peroxisome proliferator-activated receptor-γ (PPARγ), recruiting PPARγ-coactivator-1α, preventing triglyceride accumulation, and potentiating insulin signaling in vitro |
|
| DCC3977 | Pa1 Dihydrochloride | Photoswitchable epithelial sodium channel (ENaC) blocker |
|
| DCC3978 | Paba/no | Novel glutathione-S-transferase-p-activated nitric oxide donor, inhibiting proliferation and inducing apoptosis by targeting PI3K/AKT/mTOR and MEK/ERK pathways in hepatocellular carcinoma cells |
|
| DCC3979 | Pad3-in-14b | Novel potent and selective inhibitor of protein arginine deiminase 3 (PAD3), having 15600 kinact/KI values and ≥10-fold selectivity for PAD3 over PADs 1, 2, and 4. |
|
| DCC3980 | pal-1045 | Partial DAT/5-HT transporter substrate |
|
| DCC3981 | pal-1046 | Full DAT/5-HT transporter substrate |
|
| DCC3982 | Pal-12 | Novel selective LYPLAL1 activator, increasing LYPLAL1’s catalytic activity likely by enhancing the efficiency of the catalytic triad charge-relay system, confering beneficial effects in a mouse model of diet-induced obesity |
|
| DCC3983 | pal-287 | Full DAT/5-HT transporter substrate; Non-neurotoxic releasing agent of serotonin, norepinephrine, and dopamine; Full agonist at 5-HT2B and partial agonist at 5-HT2C |
|
